NICE backs two high-tech options for Barrett's oesophagus
This article was originally published in Clinica
Photodynamic therapy (PDT) has joined radiofrequency ablation (RFA) as an option for the treatment of Barrett's oesophagus within the UK's NHS. PDT features in the June round of technologies approved by NICE under its interventional procedures programme (IPP); RFA was approved in May.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.